SCHEMBL24364864

SCHEMBL24364864

C=Cc1cc(N)cnc1NC(=O)OC(C)(C)C

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP4K4 O95819 1/20 0.42
MAPKAPK2 P49137 6/20 0.38
SYK P43405 1/20 0.38
PRMT1 Q99873 1/20 0.36
ATR Q13535 1/20 0.34
EGFR P00533 3/20 0.34
NPSR1 Q6W5P4 1/20 0.34
PIK3CD O00329 1/20 0.34
ABL1 P00519 1/20 0.34
KDR P35968 1/20 0.34
PIK3CA P42336 1/20 0.34
PIK3CG P48736 1/20 0.34
BACE1 P56817 1/20 0.34
PRKDC P78527 1/20 0.34
PI4KB Q9UBF8 1/20 0.34
GSK3B P49841 1/20 0.33
DYRK1A Q13627 1/20 0.33
MAPK1 P28482 1/20 0.33
AURKA O14965 1/20 0.33
RPS6KB1 P23443 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28576272 0.84 AAK1 (0.42) MAP4K4MAPKAPK2SYKATREGFR
SCHEMBL6059338 0.82 LCK (0.40) MAP4K4MAPKAPK2SYKATRGSK3B
SCHEMBL24367667 0.81 ALDH1A1 (0.40) MAP4K4MAPKAPK2SYKPRMT1ATR
SCHEMBL31430396 0.81 MAPKAPK2 (0.41) MAP4K4MAPKAPK2SYKPRMT1ATR
SCHEMBL29477633 0.81 ALDH1A1 (0.40) MAP4K4MAPKAPK2SYKPRMT1ATR
SCHEMBL24364867 0.81 MAPKAPK2 (0.41) MAP4K4MAPKAPK2SYKPRMT1ATR
SCHEMBL6059191 0.81 MAP4K4 (0.35) MAP4K4MAPKAPK2SYKATREGFR
SCHEMBL24364156 0.81 MAPKAPK2 (0.40) MAP4K4MAPKAPK2SYKPRMT1ATR
SCHEMBL30469570 0.81 MAPKAPK2 (0.40) MAP4K4MAPKAPK2SYKPRMT1ATR
SCHEMBL29081282 0.80 MAPT (0.41) PRMT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240228478-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. 2024-07-11 US disclosed
US-20240228478-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. 2024-07-11 US disclosed
US-20220127256-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. 2022-04-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220127256-A1 COMPOUNDS AND METHODS OF USE F12, C1R, ABCG2 MAP4K4 4660/4885MAPKAPK2 4853/4885SYK 2357/4885
US-20240228478-A1 COMPOUNDS AND METHODS OF USE F12, C1R, ABCG2 MAP4K4 4660/4885MAPKAPK2 4853/4885SYK 2357/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.